Viria Plc has sold part of its shares in DNA. The selling price was EUR 16.8 million, which resulted in a profit from sales for Viria exceeding EUR 13.5 million.
“There has been a positive development in the share price of DNA and we wanted to utilise that by selling part of our shareholding in DNA. DNA forms a very large part of our investments in shares, thus selling the shares is well-founded also from the point of view of spreading the risk. DNA is a well-managed company and we don’t intend to sell more shares at this stage”, says Mika Vihervuori, CEO of Viria Plc.
More information: Mika Vihervuori, CEO, tel. 040 720 2140